The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-23), Fate Therapeutics's share price is $4.54. Fate Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was $3.74. Hence, Fate Therapeutics's PB Ratio of today is 1.22.
The historical rank and industry rank for Fate Therapeutics's PB Ratio or its related term are showing as below:
FATE'
s PB Ratio Range Over the Past 10 Years
Min: 0.4 Med: 3.84 Max: 26.54
Current: 1.22
During the past 13 years, Fate Therapeutics's highest PB Ratio was 26.54. The lowest was 0.40. And the median was 3.84.
FATE's PB Ratio is ranked better than 73.59% of 1310
companies
in the Biotechnology industry
Industry Median: 2.36
vs FATE: 1.22
During the past 12 months, Fate Therapeutics's average Book Value Per Share Growth Rate was -24.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -5.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 11.50% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 14.40% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Fate Therapeutics was 44.00% per year. The lowest was -10.80% per year. And the median was 18.90% per year.
Back to Basics: PB Ratio
Fate Therapeutics PB Ratio Historical Data
The historical data trend for Fate Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Fate Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fate Therapeutics PB Ratio Distribution
For the Biotechnology industry and Healthcare sector, Fate Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Fate Therapeutics's PB Ratio falls into.
Fate Therapeutics PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Fate Therapeutics's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Fate Therapeutics PB Ratio Related Terms
Thank you for viewing the detailed overview of Fate Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Fate Therapeutics (Fate Therapeutics) Business Description
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FATE has been successfully added to your 